|
|
||||||||
Papers In Press, published online ahead of print August 1, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cardiovascular and Metabolic Diseases, Wyeth Research, Collegeville, PA 19426
Corresponding Author: quinete{at}wyeth.com
Liver X nuclear receptors (LXRs) play key roles in regulation of cholesterol homeostasis by limiting cholesterol accumulation in macrophages within arterial wall lesion sites by a mechanism that includes upregulation of ATP-binding cassette transporters (ABCs). These atheroprotective properties distinguish LXRs as potential targets for pharmaceutical intervention in cardiovascular disease. Their associated activity for promoting lipogenesis and triglyceride accretion through activation of sterol-response element binding protein expression (SREBP-1c) however, represents a potential proatherogenic liability. A newly characterized synthetic oxysterol, N,N-dimethyl-3
Revised on August 1, 2004
Accepted on July 25, 2004
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor
-hydroxycholenamide (DMHCA), represents a gene-selective LXR modulator that mediates potent transcriptional activation of ABCA1 gene expression while exhibiting minimal effects on SREBP-1c both in vitro and in vivo in mice. DMHCA has the potential to stimulate cholesterol transport through upregulation of LXR target genes, including ABCA1, in liver, small intestine and peritoneal macrophages. When compared with known nonsteroidal LXR agonists, however, DMHCA exhibits only limited activity for increasing hepatic SREBP-1c mRNA and does not alter circulating plasma triglycerides. Cell-based studies also indicate that DMHCA enhances cholesterol efflux in macrophages and suggest a mechanism whereby this selective modulator can potentially inhibit cholesterol accumulation. DMHCA and related gene-selective ligands of LXR may have application to the study and treatment of atherosclerosis.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. M. Beyea, C. L. Heslop, C. G. Sawyez, J. Y. Edwards, J. G. Markle, R. A. Hegele, and M. W. Huff Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol J. Biol. Chem., February 23, 2007; 282(8): 5207 - 5216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Oram and A. M. Vaughan ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease Circ. Res., November 10, 2006; 99(10): 1031 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Quinet, D. A. Savio, A. R. Halpern, L. Chen, G. U. Schuster, J.-A. Gustafsson, M. D. Basso, and P. Nambi Liver X Receptor (LXR)-beta Regulation in LXR{alpha}-Deficient Mice: Implications for Therapeutic Targeting Mol. Pharmacol., October 1, 2006; 70(4): 1340 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Brunham, J. K. Kruit, T. D. Pape, J. S. Parks, F. Kuipers, and M. R. Hayden Tissue-Specific Induction of Intestinal ABCA1 Expression With a Liver X Receptor Agonist Raises Plasma HDL Cholesterol Levels Circ. Res., September 29, 2006; 99(7): 672 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Proctor, T. Jiang, M. Iwahashi, Z. Wang, J. Li, and M. Levi Regulation of Renal Fatty Acid and Cholesterol Metabolism, Inflammation, and Fibrosis in Akita and OVE26 Mice With Type 1 Diabetes Diabetes, September 1, 2006; 55(9): 2502 - 2509. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Albers, B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U. Deuschle, and M. Koegl A Novel Principle for Partial Agonism of Liver X Receptor Ligands: COMPETITIVE RECRUITMENT OF ACTIVATORS AND REPRESSORS J. Biol. Chem., February 24, 2006; 281(8): 4920 - 4930. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Telford, S. M. Lipson, P. H. R. Barrett, B. G. Sutherland, J. Y. Edwards, J. D. Aebi, H. Dehmlow, O. H. Morand, and M. W. Huff A Novel Inhibitor of Oxidosqualene:Lanosterol Cyclase Inhibits Very Low-Density Lipoprotein Apolipoprotein B100 (ApoB100) Production and Enhances Low-Density Lipoprotein ApoB100 Catabolism Through Marked Reduction in Hepatic Cholesterol Content Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2608 - 2614. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. E. Groot, N. J. Pearce, J. W. Yates, C. Stocker, C. Sauermelch, C. P. Doe, R. N. Willette, A. Olzinski, T. Peters, D. d'Epagnier, et al. Synthetic LXR agonists increase LDL in CETP species J. Lipid Res., October 1, 2005; 46(10): 2182 - 2191. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Sabol, H. B. Brewer Jr., and S. Santamarina-Fojo The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver J. Lipid Res., October 1, 2005; 46(10): 2151 - 2167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Coutinho, R. R. Singaraja, M. Kang, D. J. Arenillas, L. N. Bertram, N. Bissada, B. Staels, J.-C. Fruchart, C. Fievet, A. M. Joseph-George, et al. Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis J. Lipid Res., June 1, 2005; 46(6): 1113 - 1123. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Davies, K. L. H. Carpenter, I. R. Challis, N. L. Figg, R. McNair, D. Proudfoot, P. L. Weissberg, and C. M. Shanahan Adipocytic Differentiation and Liver X Receptor Pathways Regulate the Accumulation of Triacylglycerols in Human Vascular Smooth Muscle Cells J. Biol. Chem., February 4, 2005; 280(5): 3911 - 3919. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |